NASDAQ · CCEL
Healthcare · Medical - Care Facilities
$4.40
Up+$0.28 (+6.80%)
Updated Sep 13, 2026, 12:40 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
CCEL closed at $4.40 after 19 trading sessions, up 18.92% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $4.02 | $4.58 | $4.02 | $4.40 | 21.14K |
| Sep 10, 2026 | $4.16 | $4.4122 | $4.12 | $4.12 | 20.58K |
| Sep 9, 2026 | $4.34 | $4.34 | $4.11 | $4.11 | 3.96K |
| Sep 8, 2026 | $4.23 | $4.40 | $4.20 | $4.26 | 35.81K |
| Sep 4, 2026 | $4.20 | $4.28 | $4.20 | $4.28 | 4.36K |
| Sep 3, 2026 | $4.20 | $4.3663 | $4.0406 | $4.24 | 9.74K |
| Sep 2, 2026 | $4.1796 | $4.1796 | $4.04 | $4.04 | 2.13K |
| Sep 1, 2026 | $4.22 | $4.22 | $4.13 | $4.1646 | 6.41K |
| Aug 31, 2026 | $4.00 | $4.22 | $4.00 | $4.20 | 10.25K |
| Aug 28, 2026 | $4.24 | $4.41 | $4.00 | $4.00 | 6.45K |
| Aug 27, 2026 | $4.32 | $4.32 | $4.23 | $4.23 | 3.23K |
| Aug 26, 2026 | $4.24 | $4.5313 | $4.24 | $4.25 | 4.92K |
| Aug 25, 2026 | $4.39 | $4.60 | $4.0519 | $4.30 | 10.71K |
| Aug 24, 2026 | $4.63 | $4.63 | $4.22 | $4.39 | 69.65K |
| Aug 21, 2026 | $4.26 | $4.90 | $4.04 | $4.56 | 51.35K |
| Aug 20, 2026 | $4.08 | $4.3038 | $3.9501 | $4.18 | 19.56K |
| Aug 19, 2026 | $3.98 | $4.19 | $3.86 | $4.07 | 11.18K |
| Aug 18, 2026 | $3.71 | $4.15 | $3.71 | $3.93 | 10.92K |
| Aug 17, 2026 | $3.82 | $3.995 | $3.675 | $3.70 | 11.99K |
The latest Smart Investors Daily articles mentioning CCEL.
CCEL research
Company profile and research snapshot.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 20, 2025 | Maxim Group | Hold | — |
| Mar 4, 2025 | Maxim Group | Buy | — |
| Aug 29, 2022 | Maxim Group | Buy | — |
No generated briefing is available yet.
ChartMill · Jul 15, 2026
Cryo-Cell reported Q2 2026 earnings with a net income surprise of $0.07 per share, beating $0.00 estimates, though revenue slipped 2% YoY to $7.8M, causing after-hours shares to dip 4.8%.
Benzinga · Jul 15, 2026
Cryo-Cell International (AMEX:CCEL) reported quarterly earnings of $0.07 per share. This is a 75 percent increase over earnings of $0.04 per share from the same period last year. The company reported $7.800 million in
Benzinga · Jun 18, 2026
Finnhub · May 8, 2026
Cryo-Cell International Inc: Cryo-Cell receives acceptance of compliance plan from NYSE American...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CCEL.
